Lung　adenocarcinoma　(LUAD),　the　most　common　subtype　of　lung　cancer,　is　a　global　health　challenge　with　high　recurrence　and　mortality　rates.　The　coagulation　cascade　plays　an　essential　role　in　tumor　disease　progression　and　leads　to　death　in　LUAD.　We　differentiated　two　coagulation-related　subtypes　in　LUAD　patients　in　this　study　based　on　coagulation　pathways　collected　from　the　KEGG　database.　We　then　demonstrated　significant　differences　between　the　two　coagulation-associated　subtypes　regarding　immune　characteristics　and　prognostic　stratification.　For　risk　stratification　and　prognostic　prediction,　we　developed　a　coagulation-related　risk　score　prognostic　model　in　the　Cancer　Genome　Atlas　(TCGA)　cohort.　The　GEO　cohort　also　validated　the　predictive　value　of　the　coagulation　-related　risk　score　in　terms　of　prognosis　and　immunotherapy.　Based　on　these　results,　we　identified　coagulation-related　prognostic　factors　in　LUAD,　which　may　serve　as　a　robust　prognostic　biomarker　for　therapeutic　and　immunotherapeutic　efficacy.　It　may　contribute　to　clinical　decision-making　in　patients　with　LUAD.